Markets could be in for macro overload in the week ahead with central bankers, Friday's jobs report and OPEC dominating the headlines.» Read More
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell.
Ben Bernake smelled "shenanigans" coming out of Washington and decided not to taper, says Bob Doll, Nuveen Asset Management, discussing the looming government shutdown and its probable impact on the economy.
Carl Riccadonna, Deutsche Bank senior economist, and Hans Olsen, Barclays wealth and investment management, discuss how a government shutdown will impact markets.
Andrew Freris, Chief Investment Advisor for Asia at BNP Paribas draws comparisons between the debt mess in US with India and talks about his investment strategy.
Mad Money host Jim Cramer calls Array BioPharma a spec play. The company has 6 trials in phase 3 in progress. Its CEO Ron Squarer discusses its partnerships with big players including Novartis and Celgene.
Nektar fell 24 percent today after it announced its critical trial of a drug for chronic pain missed its primary endpoint. Mad Money viewers ask Jim Cramer their investment questions via Twitter.
This week, three firms initiated coverage on speculative development stage biotech company Pharmacyclics. Mad Money host Jim Cramer reveals the risks with this spec play.
Mad Money host Jim Cramer shares his thoughts on Dunkin' Brands. "I think Dunkin is a classic regional to national growth story," he explains.
Mad Money host Jim Cramer looks ahead to next week's action when manufacturing statistics from China are released, as well as Friday's jobs report.
Yahoo is up around 8 percent in the last 5 days. CNBC's Josh Lipton reports Yahoo has a 24 percent stake in Alibaba, and Yahoo's rise may be over excitement of a potential IPO for Alibaba. The "Fast Money" traders take their positions on Nike and gold.
If BlackBerry is sold and CEO Thorsten Heins' position is terminated, he could still rake in $55 million. CNBC's Seema Mody has the details. Adam Crowther, Public Citizen researcher, and Katherine Mangu-Ward, Reason Magazine, weigh in on CEOs' "golden parachutes."
Where to put your money in a government impacted market, with Katie Stockton, BTIG; Stephanie Link, TheStreet; Rich Peterson, S&P Capital IQ; Andres Garcia-Amaya, JPMorgan Funds; and CNBC's Rick Santelli.
CNBC's Dominic Chu reports on 3 stocks to watch in next week's trade. JC Penney is hovering around $9, nearing its record low at $8; and Walgreen will report earnings on Tuesday.
Chick Nice, pop culture commentator, and CNBC's Robert Frank discuss 3 outrages headlines from this week including Martha Stewart, Bill Gates and Barilla Baron pasta.
A report by the Center for Science in the Public Interest shows that Americans eat 450 more calories per day than in 1970. CNBC's Jane Wells explores ways to make money off that data.
Ron Weiner, RDM Financial Group CEO, explains why stocks lower on government concerns is a good thing. He is putting his money in American Tower, Qualcomm, and JPMorgan.
Kenny Polcari, O'Neil Securities director, and CNBC's Sue Herera look ahead to next week. At the top of the list is the budget battle in Washington.
The FMHR traders reveal their final trades of the hour.
Daniel Stecich, TJM Institutional Services, joins CNBC's Rick Santelli to discuss why he is placing his bets to the downside as a budget battle looms ahead on Capitol Hill.
CNBC's Simon Hobbs reports on all the market moving events from Europe today, as global markets eye a possible U.S. government shutdown.